Ardelyx presents real-world tenapanor effectiveness analysis in dialysis patients at ASN Kidney Week 2026

By Public Technologies
  • Ardelyx flagged new research on hyperphosphatemia management scheduled for presentation at ASN Kidney Week 2026 in Denver.
  • Data include real-world analyses of tenapanor use alongside phosphate binders, focusing on how patients fare in routine clinical practice.
  • Separate work examines patient-reported challenges in managing hyperphosphatemia, highlighting treatment burden and adherence obstacles.
  • Another analysis links long-term hyperphosphatemia exposure in dialysis patients with higher risks of illness and death.
  • An exhibitor session will outline XPHOZAH’s mechanism, safety, and practical add-on use for patients not reaching guideline phosphorus targets on binders.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardelyx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050801PRIMZONEFULLFEED9839302) on October 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.